About this historical patient account: The information below describes reported observations from one case. It does not establish treatment efficacy, safety, a causal relationship or an expected outcome. Outcomes vary, and reported improvement does not demonstrate cure. Do not change prescribed medicines or delay established care based on this account.

Intervention context: This account does not establish that the cell, growth-factor or other biological interventions described are approved or effective for this diagnosis. Some may be investigational. A qualified specialist should explain the current evidence, regulatory status, alternatives, uncertainties and risks before any treatment decision.

Patient Information:

• Name: John Clarke
• Diagnosis: Dilated Cardiomyopathy (DCM), Atherosclerosis, Cardiac Failure - Functional Class III, Pacemaker Implant
• Date of Birth (D.O.B): August 1, 1962
• Gender: Male
• Country: Australia

Treatment: Nerve Growth Factor Therapy (NGF+SCT) via intravenous injections, complemented by medical treatments to enhance neural function and promote cerebral blood flow, at Beijing Puhua International Hospital (BPIH)

History:
John Clarke, a 52-year-old male, had been experiencing intermittent chest congestion, dyspnea, and exertional dyspnea for over a decade. His condition deteriorated within the three months preceding admission, with symptoms of cyanosis and edema in his lower limbs. He was admitted to BPIH on September 26th, 2014.

Medical Condition before Nerve Growth Factor Therapy (NGF+SCT) for Dilated Cardiomyopathy:

• Shortness of breath limited walking to less than ten minutes
• Speech difficulties requiring repetition
• Inability to perform everyday activities such as playing with children and engaging in intimate relations
• Frequent dizziness upon lifting his head
• Recommended by local hospital for heart transplantation surgery

Nerve Growth Factor Therapy (NGF+SCT) for Dilated Cardiomyopathy:

• Nerve growth factor implantations via intravenous injections
• Medical treatments to improve neural function and nutrition, promote cerebral blood flow, diabetes management, anticoagulation, and other supportive therapies

Medical Condition after Nerve Growth Factor Therapy (NGF+SCT) for Dilated Cardiomyopathy:

• Significant improvement in general condition
• Able to ambulate one kilometer at a time with ease
• Improved speech and ability to perform light exercise
• Facial appearance healthier without cyanosis
• Diminished dizziness
• The account reports a decision not to proceed with transplant surgery. It does not establish that Nerve Growth Factor therapy can replace transplantation or standard heart-failure care; those decisions require specialist reassessment.

Patient Testimonial:
John Clarke is very pleased with the results of his Nerve Growth Factor Therapy, stating that they have far exceeded his expectations.